AURORA, Colorado, Sept. 12 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:

* * *

Perioperative Atezolizumab Plus Chemotherapy More Than Doubles Event-Free Survival in Resectable Stage II-IIIB NSCLC

*

(SEOUL, Republic of Korea -Saturday, September 12th 6:15 p.m. Standard Time) -Patients with resectable stage IIB-IIIB non-small cell lung cancer (NSCLC) treated with perioperative . . .

Click here for more information about our products